Back in November, the Centers for Disease Control and Prevention (CDC) released a report saying 6 percent of American adults are obese, a number that should outrage every American. If the numbers were correct, that means obesity affects over 100 million Americans, almost a quarter of the U.S. population. Although the weight of this epidemic is indeed alarming, the panel also said that the CDC’s 6 percent estimate is much too low. The committee concluded that the figure should be double.
To make matters worse, the CDC also included the following as part of their report, stating, “The original CDC calculations, while based on a high-end guess, are likely lower than what the data actually prove, and, in fact, may prove far too low.”
Now, not everyone believes that the CDC’s 5 percent overestimate is accurate. In fact, the people advising the CDC to increase the prevalence of obesity have come up with a plan that would decrease it by 10 percent. That plan includes “a plan to make the best cases possible on the effectiveness of prescription medications and reduce costs associated with the use of these medications” as well as adding employees at the CDC.
The FDA recently convened a panel of experts to evaluate the effectiveness of the obesity drug, Belviq. After examining a variety of studies, the panel recommended that the FDA put a hold on the ongoing research on Belviq. The FDA will consider the experts’ recommendation and announce their ruling by mid-2019.